Highest-materiality recent filing
Werewolf Therapeutics Q1 net loss $13.5M; sells JZP898 to Jazz and repays K2 debt
Cash and cash equivalents $46.5M as of March 31, 2026, vs $57.1M at Dec 31, 2025.
Werewolf Therapeutics announces strategic alternatives review; Q4 2025 net loss $8.4M
Engaged Piper Sandler as exclusive financial advisor to explore strategic alternatives including sale, merger, or asset sale.
Werewolf Therapeutics initiates strategic alternatives review, hires Piper Sandler
Feb 24, 2026: Werewolf (HOWL) announces exploration of strategic alternatives including sale, merger, or licensing.
Reduction in force affecting 64% of workforce; expected completion by Feb 13, 2026.
Werewolf Therapeutics receives Nasdaq deficiency notice for bid price below $1.00
Notice dated Feb 4, 2026: bid price closed below $1.00 for 30 consecutive business days.
WTX-124 monotherapy achieved 21% ORR in heavily pretreated advanced melanoma; 30% ORR in patients not primary resistant to prior immunotherapy.
Werewolf Therapeutics Q3 net loss $16.4M, cash $65.7M; key trial updates due Q4 2025
Cash and equivalents $65.7M as of Sept 30, 2025, expected to fund operations into Q4 2026.
Werewolf Therapeutics Q2 net loss $18M; WTX-124 data on track for Q4 2025
Cash $77.6M as of June 30, 2025, providing runway into Q4 2026.
Stock bid price closed below $1.00 for 30 consecutive business days, triggering Nasdaq deficiency notice.
Werewolf Therapeutics Q1 net loss $18.1M; cash $92M; WTX-124 data/FDA in H2 2025
Net loss of $18.1M in Q1 2025 vs $16.2M in Q1 2024; R&D spend $13.1M.
Werewolf Therapeutics reports Q4 2024 net loss of $20.4M; cash runway through Q2 2026
Cash and cash equivalents $111.0M at Dec 31, 2024; sufficient to fund operations through Q2 2026.
Werewolf Therapeutics reports Q3 net loss $16.7M; WTX-330 partial response in melanoma
Net loss $16.7M for Q3 2024 vs $8.3M in Q3 2023; cash $122.8M, runway through Q2 2026.
Werewolf Therapeutics Q2 2024 net loss $17.2M; positive clinical data for WTX-124 and WTX-330
Net loss of $17.2M in Q2 2024 vs $5.1M in Q2 2023; R&D expenses rose to $15.3M from $9.6M.
WTX-330 achieved 23-fold higher systemic IL-12 prodrug concentration vs rhIL-12 at 0.024 mg/kg; free IL-12 <1.6% of prodrug (cutoff June 12, 2024).
WTX-124 Phase 1/1b shows 3 objective responses (1 CR) in checkpoint-refractory solid tumors
3 objective responses out of 35 monotherapy-treated patients: 1 confirmed complete response, 2 partial responses.
Werewolf Therapeutics reports Q1 net loss of $16.2M; cash runway extended to Q1 2026
Net loss $16.2M in Q1 2024, up from $12.0M loss in Q1 2023; R&D expenses rose to $12.9M.
On February 19, 2025, Derek DiRocco, M.D., notified Werewolf Therapeutics, Inc. (the “Company”) of his intent to resign from the Board of Directors (the “Board”) of the Company, effective upon the Company’s 2025 annual meeting of stockholders.
On February 19, 2025, the Board of the Company, upon recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Anil Singhal, Ph.D., as a director.
Max materiality 0.80 · Median 0.65 · Most common event other_material